Additionally, ATRA has been demonstrated to increase the efficacy of anti-VEGFR2 antibodies alone and in combination with chemotherapy in preclinical breast cancer models, reverse the anti-VEGFR2-induced accumulation of intratumoral MDSCs, alleviate hypoxia, and counteract the disorganization of tumor microvessels (47). This evidence concerns the gene KDR and neoplasm.